Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
As EU Approval Moves Closer Are Governments Prepared For PrEP?

On Friday the EU's Committee for Medicinal Products for Human Use (CHMP) announced its positive opinion on Gilead’s HIV pre-exposure prophylaxis product Truvada PrEP. But with many European governments trying to control healthcare costs, the biggest issue facing Truvada PrEP might not be approval but rather reimbursement.

Published
27 July 2016
From
Seeking Alpha
South Africa: Produce HIV Drugs Locally, Says Science Minister

Durban -South Africa should advocate for the creation of local HIV drug manufacturing companies and stop depending on foreign pharmaceutical multinationals for these drugs, says Science and Technology Minister Naledi Pandor.

Published
22 July 2016
From
AllAfrica
HIV Drug Pricing Protest Interrupts PrEP Session at AIDS 2016

Protesters against the high cost of antiretroviral drugs joined forces and marched together today, interrupting a research presentation today at the 21st International AIDS Conference (AIDS 2016).

Published
21 July 2016
From
BETA blog
Challenges Loom for Point-of-Care Diagnostics

POC is likely to grow in emerging markets, where limited resources and local conditions make traditional lab-based testing less practical.

Published
13 July 2016
From
Genetic Engineering & Biotechnology News
Gilead defeats AIDS activists who claimed the company manipulated patents

Gilead Sciences won a victory last week when a federal court judge tossed a lawsuit in which an AIDS activist group accused the drug maker of manipulating the patent system in order to thwart competition for its HIV medicines. At issue was tenofovir, or TDF, which Gilead is replacing with a modified version known as TAF.

Published
13 July 2016
From
STAT
The Medicines Patent Pool Signs New Round of Generic Manufacturing Licences for HIV and Hepatitis C Treatments

The Medicines Patent Pool (MPP) announced new generic manufacturing licences today for four antiretrovirals and hepatitis C direct-acting antiviral daclatasvir. The organisation signed licences with Aurobindo, Desano, Emcure, Hetero Labs, Laurus Labs, Lupin and new partner Zydus Cadila for a total of nine new sub-licensing agreements to produce generic versions of key World Health Organization-priority HIV and hepatitis C treatments.

Published
11 July 2016
From
Medicines Patent Pool
Gilead’s new price hikes on HIV drugs anger AIDS activists

As part of a strategy to switch patients to newer HIV treatments, Gilead Sciences late last week raised prices on a pair of older HIV medications that face patent expiration. This sort of maneuver is often found in the pharmaceutical playbook, but is triggering still more criticism by AIDS activists of its overall pricing strategies.

Published
06 July 2016
From
STAT
How To Avoid Black Market HIV Drugs

HIV drugs are big business — and not just to the companies that manufacture them and the pharmacies that sell them. They are also a growing portion of the drugs flooding the black market, generally stolen or counterfeit medications.

Published
04 July 2016
From
HIV Plus
Brexit spells upheaval for EU and UK drug regulation

Britain's vote to leave the European Union spells regulatory uncertainty for drug companies, with the London-based European Medicines Agency (EMA), which approves treatments for all EU countries, expected to have to relocate. Britain's biggest drugmaker, GlaxoSmithKline, said the exit vote "creates uncertainty and potentially complexity for us in the future".

Published
30 June 2016
From
Reuters
Gilead’s single tablet regimen Odefsey receives European marketing approval for HIV treatment

The European Commission has granted marketing authorization for Gilead Sciences' once-daily single tablet regimen (STR) Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients.

Published
27 June 2016
From
PharmaBiz
← First12345...88Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close